MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuronetics, Inc. - Common Stock (NQ:STIM)

1.885 -0.065 (-3.33%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuronetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services 
From Neuronetics
Via GlobeNewswire
News headline image
Neuronetics Inc (NASDAQ:STIM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Neuronetics (STIM) reported mixed Q2 2025 results, beating revenue estimates but posting a wider-than-expected loss, causing a 9% pre-market drop. Greenbrook clinics hit record revenue. 
Via Chartmill
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes dataset 
From Neuronetics
Via GlobeNewswire
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company’s ongoing commitment to clinical innovation and excellence 
From Neuronetics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Neuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness Month
From Neuronetics
Via GlobeNewswire
News headline image
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
Policy update increases access for millions covered by Evernorth Health Services 
From Neuronetics
Via GlobeNewswire
News headline image
What's going on in today's pre-market session ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 4, 2025 ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools 
From Neuronetics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
Data selected for oral presentation reinforce previous findings on safety and efficacy 
From Neuronetics
Via GlobeNewswire
News headline image
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies 
From Neuronetics
Via GlobeNewswire
News headline image
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression 
From Neuronetics
Via GlobeNewswire
News headline image
NeuroStar® Releases Software Upgrades to Elevate Patient Care
Upgrades improve communication, streamline data management, and strengthen security 
From Neuronetics
Via GlobeNewswire
News headline image
Retractable Technologies And 2 Other Penny Stocks Executives Are Buying ↗
 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enstar Group Limited (Nasdaq – ESGR), PetIQ, Inc. (Nasdaq – PETQ), Greenbrook TMS, Inc. (OTC – GBNHF), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives 
From Neuronetics
Via GlobeNewswire
News headline image
Butterfly Network And 3 Other Stocks Under $2 Executives Are Aggressively Buying ↗
 
Via Benzinga
News headline image
NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility 
From Neuronetics
Via GlobeNewswire
News headline image
Gold Gains Over 1%; Starbucks Shares Move Higher ↗
 
Via Benzinga
News headline image
Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations ↗
Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and... 
Via Benzinga
News headline image
Crude Oil Surges 2%; B. Riley Financial Shares Plunge ↗
 
Via Benzinga
News headline image
STIM Stock Earnings: Neuronetics Misses EPS, Misses Revenue for Q2 2024 ↗
STIM stock results show that Neuronetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Dow Dips 150 Points; Monday.com Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story